BCL2 and diffuse large B-cell lymphoma: Acquired mutation of the venetoclax-binding BH3 domain in BCL2, which reduces its ability to bind venetoclax, has been characterized in CLL patients and DLBCL cell lines as a mechanism of venetoclax resistance [35,37].